Sovaldi On The Cusp: NICE Wants More Data On Subgroups
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead’s high-cost hepatitis C drug is surprisingly close to making it through U.K.’s cost-effectiveness watchdog.